Edition:
United States

Eli Lilly and Co (LLY)

LLY on New York Consolidated

81.16USD
23 Sep 2016
Change (% chg)

$-0.13 (-0.16%)
Prev Close
$81.29
Open
$80.97
Day's High
$81.46
Day's Low
$80.77
Volume
2,197,653
Avg. Vol
3,822,153
52-wk High
$88.48
52-wk Low
$67.88

Summary

Name Age Since Current Position

John Lechleiter

62 2013 Chairman of the Board, President, Chief Executive Officer

Derica Rice

51 2013 Chief Financial Officer, Executive Vice President - Global Services

Maria Crowe

56 2012 President - Manufacturing Operations

Jan Lundberg

62 2010 Executive Vice President - Science and Technology, President - Lilly Research Laboratories

Melissa Barnes

48 2013 Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Michael Harrington

53 2013 Senior Vice President, General Counsel

Stephen Fry

50 2011 Senior Vice President - Human Resources and Diversity

Enrique Conterno

49 2009 Senior Vice President and President - Lilly Diabetes

Susan Mahony

51 2011 Senior Vice President and President - Lilly Oncology

Barton Peterson

57 2009 Senior Vice President - Corporate Affairs and Communications

David Ricks

48 2012 Senior Vice President, President - Lilly Bio-Medicines

Jeffrey Simmons

48 2008 Senior Vice President and President - Elanco Animal Health

Fionnuala Walsh

56 2007 Senior Vice President - Global Quality

Alfonso Zulueta

53 2014 Senior Vice President and President - Emerging Markets

Ellen Marram

69 2013 Lead Independent Director

Ralph Alvarez

60 2009 Independent Director

Katherine Baicker

44 2011 Independent Director

Michael Eskew

66 2008 Independent Director

J. Erik Fyrwald

56 2005 Independent Director

R. David Hoover

70 2009 Independent Director

Karen Horn

72 2012 Independent Director

William Kaelin

58 2012 Independent Director

Juan Luciano

54 2016 Independent Director

Franklyn Prendergast

71 1995 Independent Director

Marschall Runge

61 2013 Independent Director

Kathi Seifert

66 1995 Independent Director

Jackson Tai

66 2013 Independent Director

Biographies

Name Description

John Lechleiter

Dr. John C. Lechleiter, Ph.D. is no longer Chairman of the Board of Eli Lilly And Co., effective May 31, 2017. He resigned as President, Chief Executive Officer effective December 31, 2016. A Ph.D. chemist by training, Dr. Lechleiter has over 37 years of experience with the company in a variety of roles of increasing responsibility in research and development, pharmaceutical operations, and corporate administration. As a result, he has a sound understanding of pharmaceutical research and development, sales and marketing, and manufacturing.

Derica Rice

Mr. Derica W. Rice is Chief Financial Officer, Executive Vice President - Global Services of the Company. Mr. Rice served as Acting Chief Executive Officer of the Company from May 13, 2013 to July 8, 2013. He has been appointed as Chief Financial Officer since May 2006 & Executive Vice President - Global Services of the Company since January 2010. He joined the company in 1990 as an international treasury associate. He has held leadership roles during his tenure, including chief financial officer for Lilly Canada, executive director and chief financial officer for European operations based in London, and the general manager of Lilly United Kingdom and Republic of Ireland. Prior to becoming Lilly's CFO in 2006, Rice had been the vice president and controller since July 2003. Mr. Rice received a bachelor's degree in electrical engineering from Kettering University (formerly the GMI Engineering & Management Institute) in 1988 and a master's degree in business administration in 1990 from Indiana University. In 2009, Rice was selected as one of the "Most Powerful Executives in Corporate America" by Black Enterprise magazine and he was selected as one of Diversity MBA magazine's "Top 100 Under 50 Executives." He serves as a member of the board of directors for Target Corporation, Clarian Health North and The Center for Leadership Development. He serves as a member of the Indiana University Board of Trustees and the Board of Governors of the Indianapolis Museum of Art.

Maria Crowe

Ms. Maria A. Crowe is President - Manufacturing Operations of the Company. Ms. Crowe was senior vice president for global drug product manufacturing of the company. She was general manager of manufacturing sites in Ireland and Puerto Rico. As head of manufacturing operations, she will lead a network of 22 sites in 13 countries and also will have responsibility for Lilly's global contract-manufacturing organization. She has served as senior vice president for global drug product manufacturing since August 2009. In this role, she has overseen all of Lilly's drug product manufacturing, packaging, and distribution operations. In her 29-year Lilly career, she has held roles in drug product and active pharmaceutical ingredient (API) manufacturing, as well as in sourcing and procurement. Prior to her current role, she was vice president for drug product manufacturing in the Americas ( the United States and Latin America). She served as general manager at Lilly's Kinsale, Ireland, plant; general manager of Lilly del Caribe in Puerto Rico; and plant manager of Lilly's Elanco manufacturing plant at the former Tippecanoe manufacturing site. She holds a bachelor's degree in industrial management from Purdue University.

Jan Lundberg

Dr. Jan M. Lundberg Ph.D., is an Executive Vice President - Science and Technology, President - Lilly Research Laboratories of the Company. Dr. Lundberg has a Ph.D. from Sweden's Karolinska Institute, where he was a professor in the department of pharmacology before moving to industry. Prior to Karolinska, he attended Gustavus Adolphus College in Minnesota and the University of Gothenburg in Sweden. He has been a member of the Swedish Medical Research Council and of the Advisory Board for Drug Approvals at the Swedish Medical Product Agency. In January 2003, he was appointed Honorary Doctor of Pharmacy at Uppsala University. During the last 10 years at AstraZeneca, as head of global discovery research, he was instrumental in delivering 150 drug candidates to the company's pipeline. He had a role in external activities, including in-licensing of projects and technologies, as well as acquisitions of biotech companies. His organization was with both small molecules and biologics. For the past seven years, he has been an executive vice president and member of the senior executive team, reporting to the CEO of AstraZeneca.

Melissa Barnes

Ms. Melissa S. Barnes is Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer of the Company, since January 2013.

Michael Harrington

Mr. Michael J. Harrington is Senior Vice President, General Counsel of the Company. He led significant efforts during 2013 to develop and implement the "Protect Lilly" program, the company's comprehensive data protection program. Mr. Harrington also served as a trusted advisor to the executive team and has contributed to a strong ethics and compliance tone within the company.

Stephen Fry

Mr. Stephen F. Fry is Senior Vice President - Human Resources and Diversity of the Company. Mr. Fry was the managing director of Lilly's Australian affiliate from 2004 -- 2007, then served in human resources capacities as executive director for the intercontinental region and Japan until becoming vice president for bio-medicines and emerging markets. He joined Lilly in 1987 as a scientific systems analyst in the company's former Greenfield, Ind. laboratories, moving into human resources in 1992. He assumed a leadership role when he was selected as the director of human resources for Lilly's United Kingdom affiliate in 1998, followed by executive director positions for both Lilly's U.S. affiliate and the pharmaceutical operations area. He has a bachelor's degree in business from the University of Indianapolis.

Enrique Conterno

Mr. Enrique A. Conterno is Senior Vice President and President - Lilly Diabetes of the Company. He became president of the diabetes business unit on November 1, 2009. The business unit, which becomes operational on January 1, 2010, enhances the company’s diabetes focus. Since January 2009, he had served as president of Lilly USA. He is a member of Lilly's operations committee and senior management council. He earned a master's of business administration degree at Duke University in 1992. He earned his bachelor’s degree in mechanical engineering from Case Western Reserve University in 1989. He joined Lilly as a sales representative in 1992. From 1993 to 1995, he held as a financial analyst, marketing associate, and business development manager. In 1996, Conterno became sales and marketing director for the Peru affiliate, and in 1998, he became the sales and marketing director for Lilly's affiliate in Brazil. In 2000, he was named executive director of marketing for the intercontinental region and Japan. He served as president and general manager for Lilly’s operations in Mexico in 2003, and was named vice president of Lilly USA's neuroscience business unit in July 2006. In June 2008, he was named senior vice president of health care professional markets for Lilly USA.

Susan Mahony

Dr. Susan Mahony Ph.D., is Senior Vice President and President - Lilly Oncology of the Company. Dr. Mahony has been Senior Vice President, Human Resources and Diversity (May 2009 – February 2011). Ms. Mahony joined Lilly eight years ago, after a decade in sales and marketing roles in the United Kingdom and Europe for Amgen, Bristol-Myers Squibb, and Schering-Plough. She was named general manager of Lilly Canada in 2008 after roles in global marketing and new product development, including a leadership in the development of Cymbalta(R). She was the Six Sigma leader for Lilly's sales and marketing component. Ms. Mahony received her bachelor's degree and Ph. D. in pharmacy from Aston University in Great Britain, and holds an MBA from the London Business School.

Barton Peterson

Mr. Barton R. Peterson is Senior Vice President - Corporate Affairs and Communications of the Company. He served as mayor of Indianapolis, Indiana from 2000 to 2007. From 2008 to 2009, he was managing director at Strategic Capital Partners, LLC, and distinguished visiting professor of public policy at Ball State University.

David Ricks

Mr. David A. Ricks has been appointed as Chairman of the Board, President, Chief Executive Officer of the Company. He has been appointed as President, Chief Executive Officer, Director effective January 1, 2017 and chairman of the board effective June 1, 2017. Mr. Ricks formerly was general manager of Lilly affiliates in China and Canada. Ricks' responsibilities will include the U.S., Japan, and Europe. Bio-Medicines encompasses the therapeutic areas of neuroscience, cardiovascular, autoimmunity, musculoskeletal, and urology. He is a 15-year Lilly veteran, has led three of Lilly's important affiliates: the U.S., China, and Canada. As president of Lilly USA since 2009, Ricks spearheaded a new operating model focused on customer satisfaction and revenue growth while preparing for patent losses and changes to the health care system in the United States. He joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving into key international roles for seven years - as president and general manager of Lilly's affiliate in China, one of the world's fastest-growing pharmaceutical markets. He previously served as general manager of Lilly Canada after roles there as director of pharmaceutical marketing and national sales director. He earned a bachelor's degree in business from Purdue University and an MBA from Indiana University. Prior to joining Lilly, he held positions with Hewlett-Packard Corp. and IBM.

Jeffrey Simmons

Mr. Jeffrey N. Simmons is Senior Vice President and President - Elanco Animal Health of the Company, since January 2008.

Fionnuala Walsh

Dr. Fionnuala M. Walsh Ph.D., is Senior Vice President - Global Quality of the Company, since July 2007. Her presence on the company's senior governance committee is expected to further underscore Lilly's ongoing commitment to quality. She earned a bachelor's degree and doctoral degree in chemistry from University College Dublin. She joined Lilly's Kinsale, Ireland , manufacturing site in 1988 as a technical services chemist. After positions there, she moved into a role as global quality leader at the Lilly Corporate Center in Indianapolis in 2002. In January 2003 , she was named executive director of quality for U.S. drug product and Lilly Technology Center operations. In July 2005 , she was named vice president of global quality operations, and, in June 2007 , she was named senior vice president of global quality.

Alfonso Zulueta

Mr. Alfonso Zulueta is Senior Vice President and President - Emerging Markets of the Company. Zulueta received a bachelor's degree in economics from De La Salle University in the Philippines in 1982 and an MBA from the University of Virginia in 1987. In his 25 year career with Lilly, Zulueta has held several sales and marketing leadership positions in the United States before becoming general manager for the Philippines affiliate in 1995. He served as president of Asian operations prior to being promoted in 2008 to his current role as president and general manager of Lilly Japan, the company's second largest market and affiliate behind only the U.S.

Ellen Marram

Ms. Ellen R. Marram is Lead Independent Director of the Company. She served as Acting Chairperson of the Board of the Company from May 13, 2013 to July 8, 2013. She is President, The Barnegat Group LLC. Ms. Marram began serving as the board's lead director in April 2012. Ms. Marram is the president of The Barnegat Group LLC, a firm that provides business advisory services. She was a managing director at North Castle Partners, LLC from 2000 to 2005 and served as an advisor to the firm from 2006 to 2010. From 1993 to 1998, Ms. Marram was president and chief executive officer of Pepsico's Tropicana and the Tropicana Beverage Group. From 1988 to 1993, she was president and chief executive officer of the Nabisco Biscuit Company, the operating unit of Nabisco, Inc.; from 1987 to 1988, she was president of Nabisco's grocery division; and from 1970 to 1986, she held a series of marketing positions at Nabisco/Standard Brands, Johnson & Johnson, and Lever Brothers. Ms. Marram is a member of the board of directors of Ford Motor Company and The New York Times Company, as well as several private companies. She previously served on the board of Cadbury plc. She also serves on the boards of Wellesley College, Institute for the Future, New York-Presbyterian Hospital, Lincoln Center Theater, and Families and Work Institute.

Ralph Alvarez

Mr. Ralph Alvarez is Independent Director of Eli Lilly & Co. Mr. Alvarez is executive chairman of Skylark Co., Ltd., a restaurant operator in Japan, a position he has held since January 2013. Previously, Mr. Alvarez served as president and chief operating officer of McDonald's Corporation from August 2006 until his retirement in December 2009. He also served as president of McDonald's North America, with responsibility for all the McDonald's restaurants in the U.S. and Canada. Prior to that, he was president of McDonald's USA. Mr. Alvarez joined McDonald's in 1994 and held a variety of leadership roles throughout his career, including chief operations officer and president of the central division, both with McDonald's USA and president of McDonald's Mexico. Prior to joining McDonald's, he held leadership positions at Burger King Corporation and Wendy's International, Inc. Mr. Alvarez serves on the board of directors of Skylark Co., Ltd., Lowe's Companies, Inc., and Dunkin' Brands Group, Inc. Mr. Alvarez also serves on the President's Council, the School of Business Administration Board of Overseers, and the International Advisory Board of the University of Miami. He was previously a member of the boards of McDonald's Corporation and KeyCorp.

Katherine Baicker

Prof., Dr. Katherine Baicker, Ph.D., is Independent Director of Eli Lilly and Co. She is Professor of Health Economics at the Harvard University School of Public Health, Department of Health Policy and Management; and Research Associate at the National Bureau of Economic Research Dr. Baicker has been a professor of health economics at the Department of Health Policy and Management, School of Public Health, since 2007. From 2005 to 2007, she served as a Senate-confirmed member of the Council of Economic Advisers. From 1998 to 2005, Dr. Baicker was assistant professor and associate professor of economics at Dartmouth College. In 2001 and 2002 she also served as an economist to the Council of Economic Advisers, Executive Office of the President, and in 2003 was a visiting assistant professor at the University of Chicago Harris School of Public Policy. Dr. Baicker is a commissioner of the Medicare Payment Advisory Commission and serves on the Panel of Health Advisers to the Congressional Budget Office. She is a member of the editorial boards of Health Affairs and the Journal of Health Economics, chair of the board of directors of AcademyHealth, editor of the Forum for Health Economics and Policy, and associate editor of the Journal of Economic Perspectives. She is an elected member of the Institute of Medicine.

Michael Eskew

Mr. Michael L. Eskew is Independent Director of Eli Lilly & Co. He has CEO experience with UPS, where he established a record of success in managing complex worldwide operations, strategic planning, and building a strong consumer-brand focus. He is an audit committee financial expert, based on his CEO experience and his service on other U.S. company audit committees. He has extensive corporate governance experience through his service on the boards of other companies.

J. Erik Fyrwald

Mr. J. Erik Fyrwald is Independent Director of Eli Lilly & Co. He is President and Chief Executive Officer, Univar, Inc. J. Erik Fyrwald joined Univar Inc., a distributor of industrial and specialty chemicals and provider of related services, in May 2012 as its president and chief executive officer. In 2008, following a 27-year career at E.I. duPont de Nemours and Company (DuPont), he joined Nalco Company, serving as chairman and chief executive officer until 2011, when Nalco merged with Ecolab Inc. Following the merger, Mr. Fyrwald served as president of Ecolab. From 2003 to 2008, Mr. Fyrwald served as group vice president of the agriculture and nutrition division at DuPont. From 2000 until 2003, he was vice president and general manager of DuPont's nutrition and health business. At DuPont, he held a broad variety of assignments in a number of divisions covering many industries. He has worked in several locations throughout North America and Asia. Mr. Fyrwald serves as a director of the Society of Chemical Industry, Amsted Industries, and the Chicago Public Education Fund, and he is a trustee of the Field Museum of Chicago.

R. David Hoover

Mr. R. David Hoover is an Independent Director of Eli Lilly & Co. He has extensive CEO experience at Ball Corporation, with a strong record of leadership in operations and strategy. He has deep financial expertise as a result of his experience as CEO and CFO of Ball. He also has extensive corporate governance experience through his service on other public company boards.

Karen Horn

Dr. Karen N. Horn, Ph.D., is Independent Director of Eli Lilly & Co. Ms. Horn is a former CEO with extensive experience in various segments of the financial industry, including banking and financial services. Through her for-profit and her public-private partnership work, she has significant experience in international economics and finance. Ms. Horn has extensive corporate governance experience through service on other public company boards in a variety of industries.

William Kaelin

Dr. William G. Kaelin Jr., M.D., is Independent Director of Eli Lilly and Co. He is a prominent medical researcher and academician. He has extensive experience at Harvard Medical School, a major medical institution, as well as special expertise in oncology—a key component of Lilly's business. He also has deep expertise in basic science, including mechanisms of drug action, and experience with pharmaceutical discovery research.

Juan Luciano

Mr. Juan Ricardo Luciano is Independent Director of Eli Lilly and Company., effective February 1, 2016. He joined ADM in 2011 as executive vice president and chief operating officer. He was named president in February 2014 , and in January 2015 became the ninth chief executive in ADM's 112-year history. Since joining ADM, Luciano has overseen the commercial and production activities of ADM's Corn, Oilseeds and Agricultural Services businesses, as well as its research, project management, procurement and risk management functions. He led the company's operational excellence initiatives, which seek to improve productivity and efficiency companywide, as well as the company's efforts to improve its capital, cost and cash positions. Luciano also led the company's move into ingredients. Before joining ADM, Luciano had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the performance division. Luciano is a governor of the Boys and Girls Clubs of America, and Midwest chair of the organization's National Trustees Board. He holds an industrial engineering degree from the Buenos Aires Institute of Technology.

Franklyn Prendergast

Dr. Franklyn G. Prendergast, M.D., Ph.D., is Independent Director of Eli Lilly & Co. Dr. Prendergast is a prominent medical clinician, researcher, and academician. He has extensive experience in senior-most administration at Mayo Clinic, a major medical institution, and as director of its renowned cancer center. He retired from Mayo at the end of 2014. He has special expertise in two critical areas for Lilly—oncology and personalized medicine. As a medical doctor, he brings an important practicing-physician perspective to the Board’s deliberations.

Marschall Runge

Dr. Marschall S. Runge, M.D., Ph.D., is Independent Director of Eli Lilly And Co. Dr. Runge is the Executive Dean for the School of Medicine at the University of North Carolina at Chapel Hill. In his role as Executive Dean for the UNC School of Medicine, Dr. Runge provides overall academic and clinical leadership for the School of Medicine and the UNC Health Care System. In addition to being the Chair of the Department of Medicine, Dr. Runge is also Principal Investigator and Director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC-Chapel Hill, where he has financial, human resource and strategic oversight responsibilities for the program. An honors graduate of Vanderbilt University with a B.A. in Biology and a Ph.D. in molecular biology, Dr. Runge earned his M.D. from the Johns Hopkins School of Medicine, where he was an intern and resident in internal medicine. He then completed a cardiology fellowship at Harvard's Massachusetts General Hospital and was a faculty member there prior to moving to Emory University as an Associate Professor of Medicine in 1989. Before joining the UNC faculty in 2000, Dr. Runge held the John Sealy Distinguished Centennial Chair in Internal Medicine and was Director of the Division of Cardiology and the Sealy Center for Molecular Cardiology at the University of Texas Medical Branch at Galveston. In addition to serving as a member of the Experimental Cardiovascular Sciences Study Section of the National Institutes of Health, Dr. Runge also has published over 150 peer-reviewed manuscripts.

Kathi Seifert

Ms. Kathi P. Seifert is Independent Director of Eli Lilly & Co. Ms. Seifert is a retired senior executive of Kimberly-Clark. She has strong expertise in consumer marketing and brand management, having led sales and marketing for several worldwide brands, with a special focus on consumer health. She has extensive corporate governance experience through her other board positions.

Jackson Tai

Mr. Jackson Pei Tai is Independent Director of Eli Lilly and Co., effective November 1, 2013. He serves as a non-executive director of The Bank of China Limited, Singapore Airlines, NYSE Euronext, MasterCard Incorporated, and Royal Philips NV. From 2002 to 2007, he was vice chairman and chief executive officer of both DBS Group Holdings and DBS Bank, one of the largest financial services groups in Asia. Tai joined DBS as Chief Financial Officer in July 1999 and was president and chief operating officer of DBS from January 2001 to June 2002. Prior to his appointment at DBS, Tai was an investment banker for 25 years with J.P. Morgan & Co. Incorporated. Among his assignments at J.P. Morgan, Tai was senior regional officer and head of investment banking for Asia Pacific, based in Tokyo; founder and global head of real estate investment banking, based in New York; senior regional officer and head of investment banking for the Western United States, based in San Francisco; and executive director of J.P. Morgan Securities' Japanese business, based in Tokyo. Tai serves as a trustee of Rensselaer Polytechnic Institute and a director of the Committee of 100. He is a member of the Harvard China Advisory Group and the Harvard Business School Asia-Pacific Advisory Board. He is also a director of privately-held Russell Reynolds Associates and Brookstone, Inc. Tai received his MBA in 1974 from Harvard University where he was a recipient of a Council on Graduate Medical Education fellowship. He graduated from Rensselaer Polytechnic Institute in 1972 with a Bachelors of Science degree in Management.